Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Ter Arkh. 2000;72(12):7-10.

[Results of the multicenter controlled study of the hypolipidemic drug polycosanol in Russia].

[Article in Russian]

Abstract

AIM:

To compare efficacy and tolerance of polycosanol vs besafibrate in patients with hypercholesterolemia (HCE).

MATERIAL AND METHODS:

A multicenter controlled double blind randomised trial entered 113 patients with HCE. After 5 weeks of diet the patients were randomised into two groups. 59 patients of group 1 received polycosanol (10 mg/day), 54 patients of group 2 were given besafibrate (400 mg/day) for 8 weeks.

RESULTS:

The 8-week course of treatment was completed by 103 patients (91%): 57(97%) patients of group 1 and 46(85%) patients of group 2. In group 1 total cholesterol diminished by an average of 15%, LDLP cholesterol fell by 18%, triglycerides by 15%, while in group 2 a respective decrease was 8, 11 and 6%. Side effects in group 1 were mild.

CONCLUSION:

A hypolipidemic effect of polycosanol in a daily dose 10 mg is superior to that of besafibrate in a daily dose 400 mg.

PMID:
11201841
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Loading ...
    Write to the Help Desk